In vitro evaluation of a biomaterial-based ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
In vitro evaluation of a biomaterial-based anticancer drug delivery system as an alternative to conventional post-surgery bone cancer treatment
Auteur(s) :
Bischoff, Iris [Auteur]
Johannes Gutenberg - Universität Mainz = Johannes Gutenberg University [JGU]
Tsaryk, Roman [Auteur]
Johannes Gutenberg - Universität Mainz = Johannes Gutenberg University [JGU]
Chai, Feng [Auteur]
Médicaments et biomatériaux à libération contrôlée: mécanismes et optimisation - Advanced Drug Delivery Systems - U 1008 [MBLC - ADDS]
Furst, Robert [Auteur]
Goethe University Frankfurt
Kirkpatrick, Charles James [Auteur]
Johannes Gutenberg - Universität Mainz = Johannes Gutenberg University [JGU]
Unger, Ronald E. [Auteur]
Johannes Gutenberg - Universität Mainz = Johannes Gutenberg University [JGU]
Johannes Gutenberg - Universität Mainz = Johannes Gutenberg University [JGU]
Tsaryk, Roman [Auteur]
Johannes Gutenberg - Universität Mainz = Johannes Gutenberg University [JGU]
Chai, Feng [Auteur]
Médicaments et biomatériaux à libération contrôlée: mécanismes et optimisation - Advanced Drug Delivery Systems - U 1008 [MBLC - ADDS]
Furst, Robert [Auteur]
Goethe University Frankfurt
Kirkpatrick, Charles James [Auteur]
Johannes Gutenberg - Universität Mainz = Johannes Gutenberg University [JGU]
Unger, Ronald E. [Auteur]
Johannes Gutenberg - Universität Mainz = Johannes Gutenberg University [JGU]
Titre de la revue :
Materials Science and Engineering: C
Nom court de la revue :
Mater Sci Eng C Mater Biol Appl
Numéro :
93
Pagination :
115-124
Date de publication :
2018-12-01
ISSN :
1873-0191
Mot(s)-clé(s) en anglais :
Doxorubicin
Healthy cells
Polycyclodextrin hydroxyapatite
Cancer cells
Hypoxia
Drug-delivery
Healthy cells
Polycyclodextrin hydroxyapatite
Cancer cells
Hypoxia
Drug-delivery
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Patients diagnosed with osteosarcoma are currently treated with intravenous injections of anticancer agents after tumor resection. However, due to remaining neoplastic cells at the site of tumor removal, cancer recurrence ...
Lire la suite >Patients diagnosed with osteosarcoma are currently treated with intravenous injections of anticancer agents after tumor resection. However, due to remaining neoplastic cells at the site of tumor removal, cancer recurrence often occurs. Successful bone regeneration combined with the control of residual cancer cells presents a challenge for tissue engineering. Cyclodextrins loaded with chemotherapeutic drugs reversibly release the drugs over time. Hydroxyapatite bone biomaterials coated with doxorubicin-loaded cyclodextrin should release the drug with time after implantation directly at the original tumor site and may be a way to eliminate residual neoplastic cells. In the present study, we have carried out in vitro studies to evaluate such a drug-delivery system and have shown that doxorubicin released from cyclodextrin-coated hydroxyapatite retained biological activity and exhibited longer and higher cytotoxic effects on both cancer (osteosarcoma cells) and healthy cells (primary osteoblasts and endothelial cells) compared to biomaterials without cyclodextrin loaded with doxorubicin. Furthermore, doxorubicin released from biomaterials with cyclodextrin moderately induced the expression of tumor suppressor protein p53 whereas p21 expression was similar to control cells. In addition, hypoxic conditions, which occur after implantation until blood-flow to the area is regenerated, protected endothelial cells and primary osteoblasts from doxorubicin-induced cytotoxicity. This chemo-protective effect was far less prominent for the osteosarcoma cells. These findings indicate that a hydroxyapatite-cyclodextrin-doxorubicin chemotherapeutic strategy may enhance the drug-targeting effect on tumor cells while protecting the more sensitive healthy cells for a period of time after implantation. A successful integration of such a drug delivery system might allow healthy cells to initially survive during the doxorubicin exposure period, while eliminating residual neoplastic cells.Lire moins >
Lire la suite >Patients diagnosed with osteosarcoma are currently treated with intravenous injections of anticancer agents after tumor resection. However, due to remaining neoplastic cells at the site of tumor removal, cancer recurrence often occurs. Successful bone regeneration combined with the control of residual cancer cells presents a challenge for tissue engineering. Cyclodextrins loaded with chemotherapeutic drugs reversibly release the drugs over time. Hydroxyapatite bone biomaterials coated with doxorubicin-loaded cyclodextrin should release the drug with time after implantation directly at the original tumor site and may be a way to eliminate residual neoplastic cells. In the present study, we have carried out in vitro studies to evaluate such a drug-delivery system and have shown that doxorubicin released from cyclodextrin-coated hydroxyapatite retained biological activity and exhibited longer and higher cytotoxic effects on both cancer (osteosarcoma cells) and healthy cells (primary osteoblasts and endothelial cells) compared to biomaterials without cyclodextrin loaded with doxorubicin. Furthermore, doxorubicin released from biomaterials with cyclodextrin moderately induced the expression of tumor suppressor protein p53 whereas p21 expression was similar to control cells. In addition, hypoxic conditions, which occur after implantation until blood-flow to the area is regenerated, protected endothelial cells and primary osteoblasts from doxorubicin-induced cytotoxicity. This chemo-protective effect was far less prominent for the osteosarcoma cells. These findings indicate that a hydroxyapatite-cyclodextrin-doxorubicin chemotherapeutic strategy may enhance the drug-targeting effect on tumor cells while protecting the more sensitive healthy cells for a period of time after implantation. A successful integration of such a drug delivery system might allow healthy cells to initially survive during the doxorubicin exposure period, while eliminating residual neoplastic cells.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Collections :
Date de dépôt :
2021-01-20T15:59:09Z
2024-02-21T08:08:30Z
2024-02-21T08:08:30Z